These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 3773027)

  • 41. Phenylalanine plus ultraviolet light: preliminary report of a promising treatment for childhood vitiligo.
    Schulpis CH; Antoniou C; Michas T; Strarigos J
    Pediatr Dermatol; 1989 Dec; 6(4):332-5. PubMed ID: 2616391
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [alpha-Tocopherol in the combined treatment of vitiligo].
    Koshevenko IuN
    Vestn Dermatol Venerol; 1989; (10):70-2. PubMed ID: 2609752
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phenylalanine and UVA for Vitiligo patients: probability of an effective treatment.
    Reuss S; Weiss C; Bayerl C
    Med Hypotheses; 2006; 67(1):199-200. PubMed ID: 16554122
    [No Abstract]   [Full Text] [Related]  

  • 44. Topical calcipotriene and narrowband ultraviolet B in the treatment of vitiligo.
    Kullavanijaya P; Lim HW
    Photodermatol Photoimmunol Photomed; 2004 Oct; 20(5):248-51. PubMed ID: 15379875
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Narrowband UVB therapy for vitiligo: does the repigmentation last?
    Sitek JC; Loeb M; Ronnevig JR
    J Eur Acad Dermatol Venereol; 2007 Aug; 21(7):891-6. PubMed ID: 17658996
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Photochemotherapy with topical khellin and sunlight in vitiligo.
    Orecchia G; Perfetti L
    Dermatology; 1992; 184(2):120-3. PubMed ID: 1498372
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Combination of narrow band UVB and topical calcipotriol for the treatment of vitiligo.
    Goktas EO; Aydin F; Senturk N; Canturk MT; Turanli AY
    J Eur Acad Dermatol Venereol; 2006 May; 20(5):553-7. PubMed ID: 16684283
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Decreased phenylalanine uptake and turnover in patients with vitiligo.
    Schallreuter KU; Chavan B; Rokos H; Hibberts N; Panske A; Wood JM
    Mol Genet Metab; 2005 Dec; 86 Suppl 1():S27-33. PubMed ID: 16143555
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In vivo evidence for compromised phenylalanine metabolism in vitiligo.
    Schallreuter KU; Zschiesche M; Moore J; Panske A; Hibberts NA; Herrmann FH; Metelmann HR; Sawatzki J
    Biochem Biophys Res Commun; 1998 Feb; 243(2):395-9. PubMed ID: 9480820
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A double-blind, randomized trial of 0.05% betamethasone vs. topical catalase/dismutase superoxide in vitiligo.
    Sanclemente G; Garcia JJ; Zuleta JJ; Diehl C; Correa C; Falabella R
    J Eur Acad Dermatol Venereol; 2008 Nov; 22(11):1359-64. PubMed ID: 18624857
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Repigmentation of vitiligo with punch grafting and narrow-band UV-B (311 nm)--a prospective study.
    Lahiri K; Malakar S; Sarma N; Banerjee U
    Int J Dermatol; 2006 Jun; 45(6):649-55. PubMed ID: 16796620
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ultraviolet A in vitiligo.
    El-Mofty M; Mostafa W; Youssef R; El-Fangary M; Elramly AZ; Mahgoub D; Fawzy M
    Photodermatol Photoimmunol Photomed; 2006 Aug; 22(4):214-6. PubMed ID: 16869873
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and safety of pimecrolimus cream 1% in adult patients with vitiligo: results of a randomized, double-blind, vehicle-controlled study.
    Dawid M; Veensalu M; Grassberger M; Wolff K
    J Dtsch Dermatol Ges; 2006 Nov; 4(11):942-6. PubMed ID: 17081269
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Psoralen-ultraviolet A vs. narrow-band ultraviolet B phototherapy for the treatment of vitiligo.
    Parsad D; Kanwar AJ; Kumar B
    J Eur Acad Dermatol Venereol; 2006 Feb; 20(2):175-7. PubMed ID: 16441626
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Narrow-band UVB phototherapy combined with tacrolimus ointment in vitiligo: a review of 110 patients.
    Fai D; Cassano N; Vena GA
    J Eur Acad Dermatol Venereol; 2007 Aug; 21(7):916-20. PubMed ID: 17659000
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy, predictors of response, and long-term follow-up in patients with vitiligo treated with narrowband UVB phototherapy.
    Nicolaidou E; Antoniou C; Stratigos AJ; Stefanaki C; Katsambas AD
    J Am Acad Dermatol; 2007 Feb; 56(2):274-8. PubMed ID: 17224369
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Response of vitiligo to once- vs. twice-daily topical tacrolimus: a controlled prospective, randomized, observer-blinded trial.
    Radakovic S; Breier-Maly J; Konschitzky R; Kittler H; Sator P; Hoenigsmann H; Tanew A
    J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):951-3. PubMed ID: 19496898
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Topical tacrolimus and the 308-nm excimer laser: a synergistic combination for the treatment of vitiligo.
    Passeron T; Ostovari N; Zakaria W; Fontas E; Larrouy JC; Lacour JP; Ortonne JP
    Arch Dermatol; 2004 Sep; 140(9):1065-9. PubMed ID: 15381545
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Randomized double-blind trial of treatment of vitiligo: efficacy of psoralen-UV-A therapy vs Narrowband-UV-B therapy.
    Yones SS; Palmer RA; Garibaldinos TM; Hawk JL
    Arch Dermatol; 2007 May; 143(5):578-84. PubMed ID: 17519217
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Calcipotriene and corticosteroid combination therapy for vitiligo.
    Travis LB; Silverberg NB
    Pediatr Dermatol; 2004; 21(4):495-8. PubMed ID: 15283800
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.